DLK1 and adrenal cortex carcinoma: Next, to further explore the potential for targeting DLK1 in ACC, we evaluated responses to ADCT-701 among DLK1+ human ACC cell line-derived xenograft and ACC patient-derived (PDX) models (Fig. 2I, J).